Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation

作     者：Khalid Ibrahim Bzeizi Ali Albenmousa Abdulhaleem Mohamed Shawkat Zidan Ahmed Saleh Alabbad Waleed Alhamoudi Roberto Troisi Deiter Broering 

作者机构：Department of Liver TransplantationKing Faisal Specialist Hospital and Research CenterRiyadh 12713Saudi Arabia Department on Internal medicineFaculty of MedicineMinia UniversityMina 1234Egypt Department of Liver and Small Bowel Transplantation and Hepatobiliary-Pancreatic SurgeryKing Faisal Specialist Hospital and Research CenterRiyadh 12713Saudi Arabia Organ Transplant CenterKing Faisal Specialist Hosp and Res CtrRiyadh 11211Saudi Arabia 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2021年第13卷第3期

页      面：375-383页

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

主　　题：Prolonged release Tacrolimus Liver transplantation Graft rejection Renal impairment FK level 

摘      要：BACKGROUND Once daily tacrolimus regimen was found to exhibits similar bioavailability,safety and efficacy properties compared to twice-daily tacrolimus in kidney transplantation *** To compare the efficacy and safety of once-daily prolonged release tacrolimus compared to twice-daily tacrolimus in liver transplantation *** MEDLINE,EMBASE,CENTRAL databases were searched for clinical trials until December *** outcome measured as the rate of treatment failure indicated by biopsy-proven acute rejection,Serum creatinine,graft loss,or *** reviewers independently selected studies,collected data and assessed risk of *** results are reported as risk ratio with 95%confidence interval(CI)for dichotomous *** Seven studies included with 965 *** the included studies were of moderate quality according to the risk of bias assessment using Cochrane Risk of Bias ***-proven acute rejection was reported in four studies,and pooled analysis of those studies indicated similar rejections in both twice daily and once daily tacrolimus groups(risk ratio:1.06,95%CI:0.84-1.34,n=758,I2=0%)and also we found no significant difference between both groups for renal outcome(serum creatinine;mean difference,0.001 mg/dL,95%CI:-0.042 to 0.043,n=846,I2=18.6%).Similarly,there was similar number of adverse events such as hypertension,headache,back pain,blood related disorders,infections and nausea observed in both *** The analysis findings confirm that both once daily and twice daily tacrolimus formulations are comparable in terms of efficacy and safety outcomes.